1. Home
  2. DCI vs PRAX Comparison

DCI vs PRAX Comparison

Compare DCI & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Donaldson Company Inc.

DCI

Donaldson Company Inc.

HOLD

Current Price

$88.50

Market Cap

11.7B

Sector

Industrials

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$313.82

Market Cap

9.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCI
PRAX
Founded
1915
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Pollution Control Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.7B
9.6B
IPO Year
2005
2020

Fundamental Metrics

Financial Performance
Metric
DCI
PRAX
Price
$88.50
$313.82
Analyst Decision
Buy
Strong Buy
Analyst Count
5
15
Target Price
$99.00
$572.13
AVG Volume (30 Days)
477.4K
345.8K
Earning Date
02-26-2026
05-01-2026
Dividend Yield
1.35%
N/A
EPS Growth
N/A
N/A
EPS
1.75
N/A
Revenue
$2,844,900,000.00
N/A
Revenue This Year
$4.58
N/A
Revenue Next Year
$5.08
$6,395.88
P/E Ratio
$50.64
N/A
Revenue Growth
4.05
N/A
52 Week Low
$61.17
$28.79
52 Week High
$112.84
$354.87

Technical Indicators

Market Signals
Indicator
DCI
PRAX
Relative Strength Index (RSI) 50.10 52.61
Support Level $87.11 $282.49
Resistance Level $94.26 $327.65
Average True Range (ATR) 1.93 17.99
MACD 1.07 2.42
Stochastic Oscillator 82.20 64.57

Price Performance

Historical Comparison
DCI
PRAX

About DCI Donaldson Company Inc.

Donaldson is a leading manufacturer of filtration systems and replacement parts (including air filtration systems, liquid filtration systems, and dust, fume, and mist collectors). The company serves a diverse range of end markets, including construction, mining, agriculture, truck, and industrial. Its business is organized into three segments: mobile solutions, industrial solutions, and life sciences. Donaldson generated approximately $3.7 billion in revenue in its fiscal 2025.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: